{
  "docId": "019de070-fa64-77bc-8caf-8d60d9bebc40",
  "docSlug": "35e598705f15db6c29b5dc7bc3a9d06d",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 79 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 62,
  "pageCount": 79,
  "prevPage": 61,
  "nextPage": 63,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 120,
  "notes": "Includes footnotes regarding asset impairment definitions and segment reporting structure.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-fa64-77bc-8caf-8d60d9bebc40/62",
  "deckHref": "/decks/019de070-fa64-77bc-8caf-8d60d9bebc40",
  "deckJsonHref": "/decks/019de070-fa64-77bc-8caf-8d60d9bebc40.json",
  "deckAnchorHref": "/decks/019de070-fa64-77bc-8caf-8d60d9bebc40#slide-62",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.26,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "1. Asset impairments includes loss on assets held for sale of $68M in Q121 and $96M in Q420 and YTD December 2020. 2. See footnote 3 at slide 7... 3. The remainder of Bausch Health is referred to as 'Bausch Pharma'... 4. Each of the Bausch Pharma...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "692a84d8-1c3c-4b01-8228-4c7ec7b1fc78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.75,
        "x": 0.21,
        "y": 0.17
      },
      "kind": "table",
      "text": "Amortization and Impairment tables for Bausch + Lomb and Bausch Pharma segments.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c0efc6c-ad4a-41bc-bf9e-829bb473f21c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Amortization and Impairments of Intangible Assets ($M)2",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95a5ce91-33ea-46b0-9675-21cc5fc0ae9c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "2675011b-cdf4-48d4-a7f0-f804a5e2e5fe",
      "evidence": "The slide contains a table/data: Amortization and Impairment tables for Bausch + Lomb and Bausch Pharma segments.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 79,
      "from": 21,
      "beatId": "4729803e-b632-425a-8f97-04c24718552b",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The company outlines its strategic plan and next steps",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}